Preparing for a PET Scan

A positron emission tomography (PET) scan is a nuclear medicine imaging procedure that detects metabolic and biochemical activity in tissue, making it particularly valuable in oncology, neurology, and cardiology. Proper preparation directly affects image quality and diagnostic accuracy — inadequate preparation, particularly uncontrolled blood glucose, can render a scan non-diagnostic and require rescheduling. This page covers the definition and scope of PET scan preparation, the physiological mechanism that makes these steps necessary, the clinical scenarios in which preparation varies, and the decision boundaries that determine when a scan should proceed or be postponed.

Definition and scope

PET scan preparation encompasses the dietary, medication, activity, and safety restrictions a patient must follow in the hours before the procedure to ensure that a radiotracer — most commonly fluorodeoxyglucose (FDG) — distributes and concentrates in tissue as expected. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) publishes procedural standards that define acceptable blood glucose thresholds, fasting windows, and patient screening requirements for FDG-PET.

The scope of preparation extends across four domains:

  1. Dietary restriction — typically a 4- to 6-hour fast prior to injection, with some protocols requiring up to 12 hours for specific cardiac studies
  2. Blood glucose management — most facilities require a pre-scan blood glucose level below 200 mg/dL; many oncology protocols target below 150 mg/dL (SNMMI Procedure Standard for FDG PET/CT)
  3. Physical activity restriction — strenuous exercise must be avoided for 24 hours prior to the scan to prevent muscular FDG uptake that can obscure findings
  4. Medication and hydration considerations — oral hydration with plain water is generally encouraged; diabetic medications require specific timing adjustments coordinated with the ordering physician

The Nuclear Regulatory Commission (NRC) governs the administration of radioactive materials in clinical settings under 10 CFR Part 35, which establishes requirements for radiation safety in medical use. Patients should also be aware of the broader regulatory context for radiology that governs nuclear medicine procedures.

How it works

FDG, a glucose analogue tagged with the positron-emitting isotope fluorine-18, is injected intravenously and taken up by metabolically active cells. Cancer cells, inflamed tissue, and highly active neurons preferentially accumulate FDG. When fluorine-18 decays, it emits a positron that annihilates with a nearby electron, producing two 511 keV gamma rays traveling in opposite directions. The PET scanner detects these coincident photons to reconstruct a three-dimensional activity map.

The reason fasting matters: if blood glucose is elevated, glucose and FDG compete for the same cellular uptake pathway (primarily GLUT transporters). High circulating glucose suppresses FDG uptake in target tissue, reducing scan sensitivity. For diabetic patients, this competition is clinically significant — even moderate hyperglycemia above 200 mg/dL has been shown to degrade image quality in FDG-PET oncology studies (per SNMMI procedural guidance).

The reason physical activity restriction matters: skeletal muscle, when recently exercised, dramatically increases its glucose metabolism. Active muscles will concentrate FDG, creating artifactual uptake that can be misread as pathological or obscure genuine findings in adjacent structures.

Patients are asked to remain still and avoid talking or reading during the 45- to 60-minute FDG uptake period following injection; jaw muscle and ocular muscle activity can produce FDG accumulation that complicates head and neck imaging. Facilities typically provide a quiet, dimly lit uptake room for this reason.

Common scenarios

Preparation protocols vary meaningfully across the four primary clinical indications for PET scanning:

Oncology PET/CT — the most common indication, accounting for the majority of clinical PET volume in the United States. Standard FDG protocol applies: 4- to 6-hour fast, glucose check on arrival, and a standard FDG dose of approximately 10–15 mCi (370–555 MBq) adjusted for body weight per SNMMI guidelines. Patients receive intravenous contrast for the CT component in many centers, which adds contrast allergy screening to the preparation checklist (see contrast agents for a full breakdown of contrast-related risks).

Cardiac viability PET — assesses myocardial metabolism in patients with known coronary artery disease. This protocol often requires a glucose-loading preparation or a high-fat, low-carbohydrate diet in the 24 hours before the scan to maximize myocardial FDG uptake. The preparation differs substantially from oncology protocols and must follow institution-specific cardiac imaging protocols.

Neurological PET (brain FDG) — used in dementia workup and epilepsy localization. Preparation is similar to oncology FDG with the addition of a restriction on visual and auditory stimulation during uptake; patients rest in a quiet, darkened room with eyes closed to minimize occipital and auditory cortex FDG accumulation.

Infection and inflammation PET — used in fever of unknown origin and large-vessel vasculitis workup. Protocols remain FDG-based but may have modified fasting requirements depending on the clinical context.

For patients who are also scheduled for a PET/MRI rather than PET/CT, the MRI safety screening checklist — covering implants, devices, and claustrophobia — applies in addition to standard PET preparation.

Decision boundaries

Several conditions determine whether a PET scan should proceed, be modified, or be postponed:

Blood glucose threshold — If point-of-care glucose testing on arrival exceeds the facility's threshold (commonly 200 mg/dL for oncology, though some centers set 150 mg/dL), the scan is typically rescheduled. Proceeding above threshold produces non-diagnostic images and exposes the patient to radiation without clinical benefit.

Insulin timing in diabetic patients — Long-acting insulin should generally be taken at its normal time; short-acting insulin should not be administered within 4 hours of FDG injection because it drives FDG into muscle tissue. Coordination between the nuclear medicine team and the referring endocrinologist or primary physician is standard practice for insulin-dependent patients.

Pregnancy and lactation — The American College of Radiology (ACR) and SNMMI both address radiation exposure in pregnancy under their respective safety frameworks. Fluorine-18 crosses the placenta; PET scanning during pregnancy is undertaken only when the clinical benefit clearly outweighs fetal radiation exposure risk. Breastfeeding patients are typically advised to pump and discard breast milk for approximately 12 to 24 hours post-injection, with specific duration depending on the radiotracer used.

Recent prior imaging with radiocontrast — A prior CT with iodinated contrast does not contraindicate PET but may affect the attenuation correction map used in PET/CT fusion. Nuclear medicine technologists account for this in image processing.

Claustrophobia and body habitus — PET/CT scanners have a bore diameter of approximately 70 cm in most modern configurations. Patients whose weight exceeds the table weight limit (commonly 450 lbs / 204 kg on most systems) require evaluation for alternative imaging pathways. Claustrophobia, while less prevalent with PET than with MRI, can still require anxiolytic premedication.

A complete overview of imaging modalities and how clinicians select among them is available on the radiology imaging homepage. For patients navigating the oncology imaging pathway specifically, the page on cancer screening and surveillance imaging covers how PET fits within broader surveillance frameworks.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)